Open AccessEffect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria
Author(s) -
Hannah M. Wexler,
E Molitoris,
Sydney M. Finegold
Publication year - 1991
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.35.6.1219
Subject(s) - sulbactam , bacteroides fragilis , beta lactamase inhibitors , piperacillin , ceftizoxime , clavulanic acid , anaerobic bacteria , microbiology and biotechnology , latamoxef , ampicillin , tazobactam , moxalactam , antibacterial agent , chemistry , antibiotics , cephalosporin , bacteria , biology , amoxicillin , antibiotic resistance , imipenem , pseudomonas aeruginosa , genetics
The in vitro activities of several new beta-lactam-beta-lactamase inhibitor combinations (piperacillin plus tazobactam, ceftizoxime and cefonicid with sulbactam and clavulanic acid, and ampicillin plus 8 micrograms of sulbactam per ml) were tested with anaerobic bacteria and compared with known beta-lactam-beta-lactamase inhibitor combinations and other potent antianaerobe agents. All the combinations tested (except for the cefonicid-inhibitor combinations) were active against almost all strains of the Bacteroides fragilis group. This report indicates that beta-lactamase inhibitors may improve the activity of beta-lactam agents with marginal activity against the B. fragilis group.